Ionis Pharmaceuticals Inc

詳細情報 Ionis Pharmaceuticals Inc 企業名

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

企業情報

企業コードIONS

会社名Ionis Pharmaceuticals Inc

上場日May 17, 1991

最高経営責任者「CEO」Dr. Brett P. Monia, Ph.D.

従業員数1069

証券種類Ordinary Share

決算期末May 17

本社所在地2855 Gazelle Court

都市CARLSBAD

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号92010

電話番号17609319200

ウェブサイトhttps://www.ionis.com/

企業コードIONS

上場日May 17, 1991

最高経営責任者「CEO」Dr. Brett P. Monia, Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

179.82K

-0.64%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+2.68%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

110.50K

-0.03%

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

99.49K

-0.03%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

57.02K

+30.71%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

56.80K

--

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

56.66K

+2.15%

Dr. Eric E. Swayze, Ph.D.

Executive Vice President - Research

48.55K

+0.86%

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Chairman of the Board

36.33K

+12.65%

Ms. Shannon L. Devers

Chief Human Resources Officer, Executive Vice President

15.94K

+101.50%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

179.82K

-0.64%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+2.68%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

110.50K

-0.03%

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

99.49K

-0.03%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

57.02K

+30.71%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

56.80K

--

収益内訳

通貨: USD更新時刻: Tue, Mar 4

FY2020

FY2019

事業別USD

会社名

収益

比率

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

データなし

事業別

地域別

事業別USD

会社名

収益

比率

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

株主

更新時刻: Sun, Aug 3

株主統計

種類

株主統計

比率

Fidelity Management & Research Company LLC

14.81%

The Vanguard Group, Inc.

10.26%

T. Rowe Price Investment Management, Inc.

10.15%

Capital World Investors

7.76%

BlackRock Institutional Trust Company, N.A.

5.58%

Other

51.44%

株主統計

比率

Fidelity Management & Research Company LLC

14.81%

The Vanguard Group, Inc.

10.26%

T. Rowe Price Investment Management, Inc.

10.15%

Capital World Investors

7.76%

BlackRock Institutional Trust Company, N.A.

5.58%

Other

51.44%

種類

株主統計

比率

Investment Advisor

70.89%

Investment Advisor/Hedge Fund

17.86%

Hedge Fund

13.11%

Research Firm

2.36%

Private Equity

1.60%

Sovereign Wealth Fund

1.08%

Pension Fund

0.93%

Individual Investor

0.83%

Bank and Trust

0.51%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

795

184.51M

115.78%

+8.74M

2025Q1

826

174.18M

109.45%

-1.97M

2024Q4

819

166.51M

104.84%

-2.69M

2024Q3

814

162.85M

103.55%

+6.60M

2024Q2

810

149.96M

102.64%

-3.87M

2024Q1

792

148.14M

101.63%

-5.27M

2023Q4

782

147.15M

102.53%

-3.26M

2023Q3

763

145.13M

101.24%

-1.40M

2023Q2

770

142.08M

99.29%

+364.04K

2023Q1

825

136.59M

95.51%

-5.80M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Fidelity Management & Research Company LLC

23.61M

14.84%

+924.09K

+4.07%

Mar 31, 2025

The Vanguard Group, Inc.

16.35M

10.27%

-88.61K

-0.54%

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

16.18M

10.16%

+323.67K

+2.04%

Mar 31, 2025

Capital World Investors

12.36M

7.77%

+896.58K

+7.82%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

8.90M

5.59%

+21.73K

+0.24%

Mar 31, 2025

Wellington Management Company, LLP

8.42M

5.29%

-255.73K

-2.95%

Mar 31, 2025

Bellevue Asset Management AG

7.85M

4.93%

-15.50K

-0.20%

Mar 31, 2025

State Street Global Advisors (US)

4.85M

3.04%

-581.28K

-10.71%

Mar 31, 2025

Deep Track Capital LP

4.56M

2.87%

+2.63M

+136.01%

Mar 31, 2025

Two Sigma Investments, LP

3.78M

2.37%

+1.51M

+66.38%

Mar 31, 2025

詳細を見る

43.658USD

Ionis Pharmaceuticals Inc

43.658

概要

企業名

金融